From CNBC: [published_date]

Moderna announced positive clinical trial data for three new experimental vaccines against other viruses. This advancement brings the company closer to having multiple products on the market. The vaccines target latent viruses that can remain in the body for years without causing symptoms but can reactivate later. These new vaccines include shots against norovirus, Epstein-Barr virus, and a virus that causes shingles and chickenpox. The company also expects to release data on a combination vaccine against Covid and the flu and a shot against another common herpes virus called CMV. Moderna has entered into a funding agreement with Blackstone Life Sciences to advance its flu shot program with up to $750 million in funding. CEO Stéphane Bancel stated that Moderna’s messenger RNA platform is proving successful against various diseases. The company expects to generate significant revenue from its vaccine pipeline but anticipates a break-even point in 2026.

Moderna’s experimental vaccines include a trivalent vaccine targeting three strains of norovirus, which causes the stomach flu, leading to substantial healthcare costs and approximately 200,000 deaths annually. This vaccine has shown strong immune responses and a safe profile in a phase one trial and will move to a phase three study. Moderna estimates the market for norovirus vaccines to be worth $3 billion to $6 billion annually. Another vaccine under development targets Epstein-Barr virus, which can lead to mono and increase the risk of cancer and multiple sclerosis. There is no approved shot for this virus currently, and Moderna’s vaccines are showing promise in early trials. A vaccine targeting Varicella-Zoster virus, which causes chickenpox and shingles, is also being studied by Moderna. This virus affects a large percentage of the adult population and can lead to painful and itchy rashes. Preliminary results from a trial on this vaccine have shown a strong immune response in patients.



Read more at CNBC: Moderna moves three vaccines into final stage trials